Fernando Quezada, PA-C

Fernando Quezada practices at Ava Vascular Surgery Center in Murrieta, California.

Fernando Quezada's NPI, 1851411797, was assigned on March 31, 2007. Fernando Quezada holds California license PA16181.

Fernando Quezada's primary practice is Ava Vascular Surgery Center, at 25485 Medical Center Dr, Murrieta, CA 92562 in Riverside County. The practice phone is (951) 574-6500.

Fernando Quezada's primary practice is Ava Vascular Surgery Center in Murrieta, California. The medical group on file is Graybill Medical Group. Dmand AI also links Fernando Quezada to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Fernando Quezada practices. Vendor and product names are available with a free account.

Physician assistant is Fernando Quezada's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Fernando Quezada is licensed in California.

CMS data shows 143 Medicare services from Fernando Quezada across 2 procedure codes in 2024, all of them office visits, for 107 Medicare patients. Medicare paid $9,552 for them. Every service was in an office.

CMS counts 107 Medicare patients who saw Fernando Quezada in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Fernando Quezada's median patient age at 51, with 54% women.

In 2024, Fernando Quezada wrote 525 Medicare Part D claims for 182 patients. 88% of them were for generic drugs. CMS names the drug for 247 of them, across 16 drugs with 11 or more claims each, at $2,538 in total drug cost.

Fernando Quezada accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Fernando Quezada as offering telehealth.

CMS Open Payments shows 21 general payments to Fernando Quezada from 10 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 69% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,033.